Investors Buy Eli Lilly and Company (LLY) on Weakness on Insider Selling

Traders bought shares of Eli Lilly and Company (NYSE:LLY) on weakness during trading hours on Monday after an insider sold shares in the company. $56.08 million flowed into the stock on the tick-up and $28.40 million flowed out of the stock on the tick-down, for a money net flow of $27.68 million into the stock. Of all companies tracked, Eli Lilly and had the 18th highest net in-flow for the day. Eli Lilly and traded down ($0.43) for the day and closed at $82.86Specifically, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now owns 43,580 shares in the company, valued at approximately $3,646,338.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the transaction, the insider now owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 772,003 shares of company stock valued at $64,837,441. Insiders own 0.20% of the company’s stock.

LLY has been the subject of several research reports. UBS AG lowered shares of Eli Lilly and to a “hold” rating and set a $85.00 price objective for the company. in a research report on Wednesday, July 26th. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 target price on shares of Eli Lilly and in a report on Thursday, September 28th. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the stock a “hold” rating in a report on Friday, October 6th. Piper Jaffray Companies reiterated a “buy” rating and issued a $105.00 target price on shares of Eli Lilly and in a report on Friday, October 13th. Finally, Berenberg Bank reiterated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a report on Friday, August 4th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $89.76.

The firm has a market cap of $91,240.00, a PE ratio of 20.36, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.88 earnings per share. equities analysts forecast that Eli Lilly and Company will post 4.22 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.52%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is presently 99.05%.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Ronna Sue Cohen raised its position in Eli Lilly and by 0.4% during the second quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after acquiring an additional 9 shares in the last quarter. Accredited Investors Inc. raised its position in Eli Lilly and by 0.4% during the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after acquiring an additional 14 shares in the last quarter. Northwest Quadrant Wealth Management LLC raised its position in shares of Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after purchasing an additional 19 shares during the period. Oakworth Capital Inc. raised its position in shares of Eli Lilly and by 0.3% in the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after purchasing an additional 20 shares during the period. Finally, Sfmg LLC raised its position in shares of Eli Lilly and by 0.5% in the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after purchasing an additional 20 shares during the period. 75.48% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Investors Buy Eli Lilly and Company (LLY) on Weakness on Insider Selling” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/15/investors-buy-eli-lilly-and-company-lly-on-weakness-on-insider-selling.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply